• OceansBio will raise KRW 599.99 million through a private placement of redeemable convertible preferred shares announced November 6, 2026.
• The placement comprises 46,153 shares priced at KRW 13,000 each, a 549.35% premium to the reference price.
• Next-Generation Regional New Deal & Bio Investment Partnership will subscribe for all shares, with payment due November 16, 2026.
• Proceeds will fund electronic medicine research and development as well as business operations.
• The preferred shares convert one-for-one into common shares at an initial conversion price of KRW 13,000.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OceansBio Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261106000332), on November 06, 2026, and is solely responsible for the information contained therein.